US nutritional group Abbott has booked a slide in third-quarter sales from its baby-food division thanks to September’s recall of Similac infant formula.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
For the three months to the end of September, sales from Abbott’s pediatric nutritionals division dropped 9.3% to US$679m. For the nine-month period, sales slid 4.5% to $905m.
Last month, Abbott said it would pull millions of containers of its Similac-brand infant formula after beetles were found in its products and in one plant where the product is made.
Overall, however, Abbott said it delivered a “strong” performance in the quarter and confirmed a forecast of double-digit profit growth for the full year.
“The strategic actions we’ve taken across our global businesses position us well in high-growth emerging markets as well as promising new therapeutic areas,” said Miles White, chairman and CEO of Abbott.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFor the full earnings statement from Abbott, click here.
